Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Hepatoprotective Effect of Lactiplantibacillus plantarum DSR330 in Mice with High Fat Diet-Induced Nonalcoholic Fatty Liver Disease

  • Na-Kyoung Lee (Department of Food Science and Biotechnology of Animal Resources, Konkuk University) ;
  • Yunjung Lee (Department of Food and Nutrition, Kyungnam University) ;
  • Da-Soul Shin (Department of Food and Nutrition, Kyungnam University) ;
  • Jehyeon Ra (FM MI center, Daesang Wellife) ;
  • Yong-Min Choi (FM MI center, Daesang Wellife) ;
  • Byung Hee Ryu (Jongga R&D product Division) ;
  • Jinhyeuk Lee (FM MI center, Daesang Wellife) ;
  • Eunju Park (Department of Food and Nutrition, Kyungnam University) ;
  • Hyun-Dong Paik (Department of Food Science and Biotechnology of Animal Resources, Konkuk University)
  • Received : 2023.10.19
  • Accepted : 2023.11.22
  • Published : 2024.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Lactiplantibacillus plantarum DSR330 (DSR330) has been examined for its antimicrobials production and probiotics. In this study, the hepatoprotective effects of DSR330 were examined against nonalcoholic fatty liver disease (NAFLD) in a high-fat diet (HFD)-fed C57BL/6 mouse model. To induce the development of fatty liver, a HFD was administered for five weeks, and then silymarin (positive control) or DSR330 (108 or 109 CFU/day) was administered along with the HFD for seven weeks. DSR330 significantly decreased body weight and altered serum and hepatic lipid profiles, including a reduction in triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels compared to those in the HFD group. DSR330 significantly alleviated HFD-related hepatic injury by inducing morphological changes and reducing the levels of biomarkers, including AST, ALT, and ALP. Additionally, DSR330 alleviated the expression of SREBP-1c, ACC1, FAS, ACO, PPARα, and CPT-1 in liver cells. Insulin and leptin levels were decreased by DSR330 compared to those observed in the HFD group. However, adiponectin levels were increased, similar to those observed in the ND group. These results demonstrate that L. plantarum DSR330 inhibited HFD-induced hepatic steatosis in mice with NAFLD by modulating various signaling pathways. Hence, the use of probiotics can lead to hepatoprotective effects.

Keywords

Acknowledgement

This study was supported by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, and Forestry(IPET) through the Technology Commercialization Support Program funded by the Ministry of Agriculture, Food, and Rural Affairs (MAFRA) (122040-02-2-SB010).

References

  1. Samuel VT, Shulman GI. 2018. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab. 27: 22-41. 
  2. Hyun J, Lee Y, Wang S, Kim J, Kim J, Cha JH, et al. 2016. Kombucha tea prevents obese mice from developing hepatic steatosis and liver damage. Food Sci. Biotechnol. 25: 861-866. 
  3. Michelotti GA, Machado MV, Diehl AM. 2018. NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 10: 656-665. 
  4. Durazno M, Belci P, Collo A, Grisoglio E, Bo S. 2012. Focus on therapeutic strategies of nonalcoholic fatty liver disease. Int. J. Hepatol. 2012: 464706. 
  5. Carling D, Thornton C, Woods A, Sanders MJ. 2012. AMP-activated protein kinase: new regulation, new roles? Biochem. J. 445: 11-27. 
  6. Viollet B, Guigas B, Leclerc J, Hebradrd S, Lantier L, Mounier R, et al. 2009. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol. 196: 81-98. 
  7. Moslehi A, Hamidi-zad Z. 2018. Role of SREBPs in liver diseases: a mini-review. J. Clin. Transl. Hepatol. 6: 332-338. 
  8. Smith BK, Marcinko K, Desjardins EM, Lally JS, Ford RJ, Steinberg GR. 2016. Treatment of nonalcoholic fatty liver disease: role of AMPK. Am. J. Physiol. Endocrinol. Metab. 311: E730-E740. 
  9. Assifi MM, Suchankova G, Constant S, Prentki M, Saha AK, Ruderman NB. 2005. AMP-activated protein kinase and coordination of hepatic fatty acid metabolism of starved/carbohydrate-refed rats. Am. J. Physiol. Endocrinol. Metab. 289: E794-E800. 
  10. Foretz M, Even PC, Viollet B. 2018. AMPK activation reduces hepatic lipid content by increasing fat oxidation in vivo. Int. J. Mol. Sci. 19: 2826. 
  11. Choi DJ, Kim SC, Park GE, Choi BR, Lee DY, Lee YV, et al. 2020. Protective effect of a mixture of Astragalus membranaceus and Lithospermum erythrothizon extract against hepatic steatosis in high fat diet-induced nonalcoholic fatty liver disease mice. Evid. Based Complement. Altern. Med. 2020: 8370698. 
  12. Lee NK, Park YS, Kang DK, Paik HD. 2023. Paraprobiotics: definition, manufacturing methods, and functionality. Food Sci. Biotechnol. 32: 1981-1991. 
  13. Hyun JH, Yu HS, Woo IK, Lee GW, Lee NK, Paik HD. 2023. Anti-inflammatory activities of Levilactobacillus brevis KU15147 in RAW 264.7 cells stimulated with lipopolysaccharide on attenuating NF-κB, AP-1, and MAPK signaling pathways. Food Sci. Biotechnol. 32: 2105-1991. 
  14. Kim WJ, Hyun JH, Lee NK, Paik HD. 2022. Protective effect of a novel Lactobacillus brevis strain with probiotic characteristics against Staphylococcus aureus lipoteichoic acid-induced intestinal inflammatory response. J. Microbiol. Biotechnol. 32: 205-211. 
  15. Huang Y, Wang X, Zhang L, Zheng K, Xiong J, Li J, et al. 2022. Effect of probiotics therapy on nonalcoholic fatty liver disease. Comput. Math Methods Med. 2022: 7888076. 
  16. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, et al. 2009. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 49: 989-997. 
  17. Cao F, Ding Q, Zhung H, Lai S, Chang K, Le C, et al. 2022. Lactobacillus plantarum ZJUIDS14 alleviates non-alcoholic fatty liver disease in mice in association with modulation in the gut microbiota. Front. Nutr. 9: 1071284. 
  18. Sun M, Wu T, Zhang G, Liu R, Sui W, Zhang M, et al. 2020. Lactobacillus rhamnosus LRa05 improves lipid accumulation in mice fed with a high fat diet via regulating the intestinal microbiota, reducing glucose content and promoting liver carbohydrate metabolism. Food Funct. 11: 9514-9525. 
  19. Wu T, Zhang Y, Li W, Zhao Y, Long H, Muhindo EM, et al. 2021. Lactobacillus rhamnosus LRa05 ameliorate hyperglycemia through a regulating glucagon-mediated signaling pathway and gut microbiota in type 2 diabetic mice. J. Agric. Food Chem. 69: 8797-8806. 
  20. Ryu BH, Lee KH, Kim YW, Lee DG, Yoon SC. 2007. Novel Lactobacillus plantarum from kimchi with inhibiting activities on pathogenic microorganism and use thereof. Patent. KR101485182B1. 
  21. Chang BY, Bae JH, Lim CY, Kim YH, Kim TY, Kim SY. 2023. Tricin-enriched Zizania latifolia ameliorates non-alcoholic fatty liver disease through AMPK-dependent pathways. Food Sci. Biotechnol. 32: 2117-2129. 
  22. Mashek DG. 2020. Hepatic lipid droplets: a balancing act between energy storage and metabolic dysfunction in NAFLD. Mol. Metab. 50: 101115. 
  23. Meroni M, Longo M, Dongiovanni P. 2019. The role of probiotics nonalcoholic fatty liver disease: a new insight into therapeutic strategies. Nutrients 11: 2642. 
  24. Park SY, Choi JW, On DN, Kim DP, Yoon SY, Jang WJ, et al. 2023. Anti-obesity potential through regulation of carbohydrate uptake and gene expression in intestinal epithelial cells by the probiotics Lactiplantibacillus plantarum MGEL20154 from fermented food. J. Microbiol. Biotechnol. 33: 621-633. 
  25. Polyzos SA, Kountouras J, Mantzoros CS. 2019. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism 92: 82-97. 
  26. Kim JW, Lee YS, Seol DJ, Cho IJ, Ku SK, Choi JS, et al. 2018. Anti-obesity and fatty liver-preventing activities of Lonicera caerulea in high-fat diet-fed mice. Int. J. Mol. Med. 42: 3047-3064. 
  27. Hadizadeh F, Faghihimani E, Adivi P. 2017. Nonalcoholic fatty liver disease: diagnostic biomarkers. World Gastrointest. Pathophysiol. 15: 11-26. 
  28. Draijer L, Benninga M, Koot B. 2019. Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. Expert Rev. Gastrolenterol. Hepatol. 13: 447-461. 
  29. Fang C, Pan J, Qu N, Lei Y, Han J, Zhang J. Han D. 2022. The AMPK pathway in fatty liver disease. Front. Physiol. 13: 970292. 
  30. Moslehi A, Hamidi-zad Z. 2018. Role of SREBPs in liver diseases: a mini-review. J. Clin. Transl. Hepatol. 6: 332-338. 
  31. Kim HI, Kim JK, Kim JY, Jang SE, Han MJ, Kim DH. 2019. Lactobacillus plantarum LC27 and Bifidobacterium longum LC67 simultaneously alleviated HFD-induced colitis, endotoxemia, liver steatosis, and obesity in mice. Nutr. Res. 67: 78-89. 
  32. Lee E, Jung SR, Lee SY, Lee NK, Paik HD, Lin SI. 2018. Lactobacillus plantarum strain Ln4 attenuates diet-induced obesity, insulin resistance, and changes in hepatic mRNA levels associated with glucose and lipid metabolism. Nutrients 10: 643. 
  33. Bauche IB, El Mkadem SA, Pottier AM, Senou M, Many MC, Rezsohazy R, et al. 2007. Overexpression of adiponectin targeted to adipose tissue in transgenic mice: Impaired adipocyte differentiation. Endocrinology 148: 1539-1549. 
  34. Fabbrini E, Magkos F. 2015. Hepatic steatosis as a marker of metabolic dysfunction. Nutrients 7: 4995-5019.